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Abstract  
In a treatment plan optimization problem for radiotherapy, a clinically acceptable 
plan is usually generated by an optimization process with weighting factors or 
reference doses adjusted for organs. Recent discoveries indicate that adjusting 15 
parameters associated with each voxel may lead to better plan quality. However, it 
is still unclear regarding the mathematical reasons behind it. To answer questions 
related to this problem, we establish in this work a new mathematical framework 
equipped with two theorems. The new framework clarifies the different 
consequences of adjusting organ-dependent and voxel-dependent parameters for the 20 
treatment plan optimization of radiation therapy, as well as the different effects of 
adjusting weighting factors versus reference doses in the optimization process. The 
main discoveries are threefold: 1) While in the organ-based model the selection of 
the objective function has an impact on the quality of the optimized plans, this is no 
longer an issue for the voxel-based model since the entire Pareto surface could be 25 
generated regardless the specific form of the objective function as long as it satisfies 
certain mathematical conditions; 2) A larger Pareto surface is explored by adjusting 
voxel-dependent parameters than by adjusting organ-dependent parameters, 
possibly allowing for the generation of plans with better trade-offs among different 
clinical objectives; 3) Adjusting voxel weighting factors is preferred to adjusting the 30 
voxel reference doses since the Pareto optimality can be maintained.   
2 M.Zarepisheh et al. 
2 
 1. Introduction 
 
Treatment planning in cancer radiation therapy can be treated as a decision-making 
problem. Planner seeks for a treatment plan to deliver a certain amount of prescription 
dose to a cancerous target, while sparing dose to nearby critical structures and organs at 5 
risks. The apparent conflicts between those objectives make a multi-criteria decision-
making technique an appropriate tool to solve this problem. The main idea of the multi-
criteria technique is to reduce the size of candidate set of plans by considering only those 
plans, called Pareto plans, for which it is impossible to improve some objectives without 
worsening others. The next step is to look for a clinically acceptable plan under the trade-10 
offs between different criteria among the set of Pareto plans, referred to as Pareto surface. 
There exist several methods to handle this complicated procedure, such as fine-tuning 
optimization parameters in a trial-and-error fashion or by some heuristic approaches 
(Xing et al., 1999a; Xing et al., 1999b), pre-computing a well discrete representative of 
Pareto surface and navigating among them (Küfer et al., 2000; Cotrutz et al., 2001; 15 
Hamacher and Küfer, 2002; Lahanas et al., 2003; Küfer et al., 2003; Craft et al., 2006; 
Thieke et al., 2007; Shao and Ehrgott, 2008; Craft and Bortfeld, 2008; Monz et al., 2008; 
Hong et al., 2008; Craft and Monz, 2010; Craft et al., 2012), and prioritizing the 
evaluation criteria to avoid sacrificing those goals of more importance while improving 
those less important ones (Langer et al., 2003; Jee et al., 2007; Wilkens et al., 2007; 20 
Deasy et al., 2007; Clark et al., 2008; Long et al., 2012; Falkinger et al., 2012). Among 
them, fine-tuning optimization parameters is arguably the most common paradigm.  
In the optimization parameter-tuning regime, a commonly used approach is to adjust 
organ-dependent parameters, such as the weighting factors and the prescription doses for 
the PTV and the thresholds for the critical organs. The planner tries to achieve clinical 25 
goals, like dose-volume constraints, by manipulating the organ-dependent parameters. 
Many biological-based and dose-based evaluation criteria have also been introduced by 
researchers into the radiotherapy optimization, e.g. minimum and maximize dose, mean 
dose, equivalent uniform dose (EUD), generalized equivalent uniform dose (gEUD), 
tumor control probability (TCP), and normal tissue complication probability (NTCP) 30 
(See Romeijn et al., 2004 and references therein). Clinical experiments have 
demonstrated a great impact of using different evaluation criteria in the optimization 
process on the optimized plan quality (Craft et al., 2005; Kessler et al., 2005; Xia et al., 
2005). From the mathematical viewpoint, different criteria result in different Pareto 
surfaces. Romeijn et al. (2004) and Hoffmann et al. (2008) showed that some organ 35 
criteria generate the same Pareto surface; however, there are still a wide variety of criteria 
leading to different Pareto surfaces. So far there is no general agreement on the choice of 
the objective function and it still remains unanswered as for the question of “which 
evaluation criterion leads to a better treatment plan?” In this paper, we will show that this 
issue can be withdrawn by exploiting voxel-based optimization model. In our model, a 40 
large Pareto surface exist and different parts of this surface are explored by applying 
different set of organ evaluation criteria. Moreover, the entire Pareto surface is explored 
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by a voxel-based optimization model, as long as the voxel penalty terms and their 
derivatives are increasing functions.  
The second motivation of this work is from the recent research works about voxel-
based optimization models (Cotrutz and Xing, 2002, 2003; Wu et al., 2003; Yang and 
Xing, 2004; Breedveld et al., 2007; Shou et al., 2005), in which one tunes parameters 5 
associated to each voxel in the objective function, as opposed to the organ-based model 
in which all voxels within a specific organ are tied together and treated equally in the 
objective function. It has been demonstrated that the voxel-based optimization tends to 
result in more qualified plans compared to the conventional organ-based approaches for 
clinical cases. Moreover, voxel-based optimization planning also facilitates interactive 10 
treatment planning by providing specific access to certain parts of the dose-volume 
histogram (DVH) curves and isodose layouts of interest. If a specific part of the DVH or 
isodose curves does not comply with the clinician’s requirements, the planner can pick 
out the involved voxels and adapt their contributions in the objective function (Cotrutz 
and Xing, 2002, 2003). Up to now, there are two different schemes for adjusting voxel 15 
penalty terms in the objective function: voxel weighting factor adjustment  (Cotrutz and 
Xing, 2002, 2003; Wu et al., 2003; Yang and Xing, 2004; Breedveld et al., 2007; Shou et 
al., 2005) and voxel reference dose1 adjustment  (Lougovski et al., 2010; Wu et al., 
2003).  
Despite the success achieved by the voxel-based model in clinical studies, those 20 
models are mainly proposed heuristically and the fundamental reasons regarding the 
efficacy of them is unclear. In this paper we aim at building a mathematical framework 
for this voxel-based optimization approach, which enables us to answer the following 
questions naturally raised regarding this model: 1) Why do voxel-based models lead to 
better plan quality than organ-based models? 2) How much improvement in DVH curves 25 
can be expected by utilizing the voxel-based approach compared to the conventional 
organ-based approach?  In particular, can we expect to improve some parts of the DVH 
curves without worsening other parts? 3) What is the appropriate voxel-based objective 
function? 4) What is the difference, in terms of plan quality, between adjusting voxel 
weighting factors and voxel reference doses, and which one is preferred? 30 
This paper unfolds as follows. The new framework is presented in Section 2.  Section 
3 elaborates on the results of the new framework and clarifies the differences between the 
variants of parameter adjustment. Finally, Section 4 is devoted to the conclusions and 
future researches.                   
 35 
   
2. A New Framework for Treatment Optimization 
 
2.1 Three Different Pareto Surfaces   
 40 
Pareto optimality is an inevitable part of the inverse treatment planning when approached 
                                                      
1 It has been referred to as the prescription dose in literature. 
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from the direction of multi-criteria optimization. It helps us to get rid of the so-called 
non-Pareto plans that are not worth consideration. Generally, the Pareto optimal solutions 
are those feasible ones for which it is impossible to improve some criteria without 
deteriorating others. Equivalently speaking, improvement at no cost is possible for non-
Pareto solutions, while this is impossible for Pareto ones.  5 
Pareto optimality is defined with respect to specific criteria used in evaluating the 
plan quality. In intensity modulated radiation therapy (IMRT) literature, Pareto optimality 
has been conventionally defined based on the evaluation criteria (objective functions) 
associated to the organs. At least one evaluation criterion is given to each organ and a 
plan is called Pareto optimal if there does not exist another plan that is better in terms of 10 
at least one criterion and not worse with respect to every other criterion. For example, if 
we consider the maximum dose as an evaluation criterion for each organ at risk (OAR) 
and the minimum dose for the planning target volume (PTV), then a plan is Pareto 
optimal if it is impossible to decrease the maximum dose in one OAR without increasing 
the maximum dose in at least one other OAR or decreasing the minimum dose in PTV.  15 
Since the traditional definition of Pareto optimality in IMRT is based on the given 
evaluation criteria, the set of the Pareto solutions (Pareto surface) would depend on the 
specific evaluation criteria used in the studies, and it is not clear in advance which Pareto 
surface includes a plan with clinically better trade-offs. For example, a TCP/NTCP-based 
Pareto surface may contain a better plan for one patient, while a gEUD-based Pareto 20 
surface may include a better plan for another one.  
Here, we define Pareto optimality using the DVH and dose distribution as the 
evaluation criteria are the most common standards to evaluate the plan quality. For the 
sake of simplicity, we treat the PTV over-dosing and under-dosing equally; however, the 
results could be generalized easily.    25 
1- ( OECX ): A treatment plan is called organ evaluation criteria Pareto (OEC 
Pareto), if improvement in some organ evaluation criteria is only possible at the 
cost of another organ evaluation criterion. For instance, the organ evaluation 
criteria could be the maximum dose to OAR and the minimum dose to the PTV. 
In this case, the set of all Pareto treatment plans (Pareto surface) is denoted by30 
OECX .  
2-  ( DDX ): A treatment plan is called dose distribution Pareto, if it is impossible to 
improve the radiation doses in some voxels without worsening those in other 
voxels (improvement of doses in PTV voxels means getting closer to the 
prescribed dose, while that in voxels in OARs means delivering less radiation). 35 
Let DDX denote the set of all Pareto treatment plans in this case. 
3- ( DVHX ): A treatment plan is called DVH Pareto, if we cannot improve a certain 
part of the DVH curve of an organ without deteriorating either other part of that 
DVH or the DVH curves of other organs. Similarly, we denote the set of all 
Pareto plans in this case by DVHX .  40 
In fact, the OEC Pareto surface is the commonly used one in current IMRT treatment 
planning. In the next two subsections we will show that how we can explore these 
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surfaces and also we will prove their relationship. To facilitate reading, hereafter we refer 
to dose distribution Pareto optimality as Pareto optimality, and dose distribution Pareto 
surface as Pareto surface.   
 
2.2 Exploring Pareto Surfaces 5 
 
In commonly used organ-based treatment planning, at least one evaluation criterion (e.g., 
maximum, mean, or minimum organ dose) is associated with each organ, and a desired 
plan is obtained by finding an appropriate tradeoff between these criteria. All voxels 
within a specific organ are weighted equally in each organ criterion. Mathematically 10 
speaking, each criterion is a function of the corresponding voxel doses in this organ that 
is invariant under permutation of voxel indices. As opposed to the organ-based model, a 
voxel-based model allocates non-uniform penalty to the voxels. Let us consider a typical 
IMRT inverse planning problem where the fluence map x  is the decision variable. Here 
we just consider IMRT optimization problem for the sake of simplicity, and the proposed 15 
framework can be easily applied to any other treatment plan optimization problems (e.g., 
volumetric modulated arc therapy). 
 Problems (1) and (2) demonstrate a typical voxel-based and an organ-based model, 
respectively: 
    0( ) argmi ( ),nx j j j
S j v
x Dw w F x
σσ
≥
∈ ∈
= ∑ ∑  (1) 20 
 0( ) argm )(inx
S
x w w G xDσ σ σ
σ
≥
∈
= ∑ , (2)                    
where S T C= U is the set of structures with T accounting for the tumor andC for critical 
structures, vσ denotes the set of voxels belong to the structureσ . jw and wσ are the 
weights corresponding to the voxel j in the voxel-based model and the structureσ in the 
organ-based model. D denotes the dose deposition matrix and its entry jkD  specifies the 25 
dose received by the voxel j  from a beamlet k  at its unit intensity. jD  is the j th row 
of matrix D  that corresponds to voxel j , and Dσ  is the set of rows corresponding to the 
organ σ . jF is a voxel penalty function, andGσ is an organ penalty function. 
In Problem (1), each voxel has its own penalty contribution in the objective function 
with its specific parameter such as jw  defining its importance. For target voxels, it is 30 
preferred to have dose close to the prescription value rσ , while low radiation dose is 
desirable for the voxels belong to OARs.  Therefore, the penalty functions for voxels in 
OARs should be the increasing functions of dose, and penalty functions for tumor’s 
voxels should be increasing functions of deviation to the prescribed value.  
The following theorem reveals that we can explore the OEC and dose distribution 35 
Pareto surfaces by employing organ-based and voxel-based models respectively. The 
proof of this theorem is given in the Appendix.    
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Theorem 1: 
a- The optimal solutions of Problem (2) are OEC Pareto with respect to the criteria 
G; i.e., 
0
( ) O
w
ECx w
>
⊂U X
 5 
 
b- Let jF be increasing functions for each  ,, sjC vσ ∈ ∈ and  increasing functions of 
| |j x rD
σ σ−  for each  ,, sjT vσ ∈ ∈ then       
0
( ) DD
w
x w
>
⊂U X
 
c- Let jF and its derivative be increasing functions for each  ,, sjC vσ ∈ ∈ and  10 
increasing functions of | |j x rD
σ σ−  for each  ,, sjT vσ ∈ ∈  and the derivative of 
F  be positive on its domain , then       
0
( ) DD
w
x w
>
=U X  
The first part of the above theorem shows that some parts of the OEC Pareto surface 
can be explored by organ-based model. In fact, we are able to generate almost all Pareto 15 
points which are called properly Pareto solutions and we might miss the others referred to 
as non-properly Pareto solutions (Ehrgott, 2005; Miettinen, 1999). The second part of the 
theorem reveals that if the voxel penalty functions are appropriate increasing functions, 
then the whole Pareto surface, except for non-properly Pareto points, could be explored 
by the voxel-based model. The third part of the theorem states that the whole Pareto 20 
surface could be explored provided that the voxel penalty functions and their derivatives 
are appropriate increasing functions and the derivatives are positive on their domains. 
Moreover, it is easy to show that having the increasing derivatives results in convexity 
and assures the global optimality.  
While choosing the set of appropriate evaluation criteria is a controversial issue for 25 
organ-based model, the above theorem tells us this is not anymore an issue for voxel-
based model. In fact, almost entire Pareto surface could be explored, as long as the voxel 
penalty functions are appropriate increasing functions, and the whole Pareto surface 
could be generated if the derivatives are increasing and positive as well.  In particular, 
this means generating the DDX  is irrespective of the specific forms of the penalty 30 
functions. For instance, by employing the following popular power penalty function, we 
are able to explore almost entire Pareto surface by changing the voxel-based weights 
regardless the value of the exponent qσ providing that 1.qσ >   
 0 ( ) |min |x j j j j
C Tj
q
v j v
qw x w xD rDσ σ
σ σ
σ
σ σ
≥
∈ ∈∈ ∈
+ −∑ ∑∑ ∑  (3) 
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Since the derivative of the power function is not positive everywhere in (3), we might 
miss non-properly Pareto points. In order to catch the entire Pareto surface we can use, 
for example, the following exponential penalty function. 
0 exp( ) exp(|m )in |x j j j j
C Tj v j v
w x w x rD D
σ σ
σ
σ σ
≥
∈ ∈∈ ∈
+ −∑ ∑∑ ∑  
 5 
2.3 Relationship between Pareto Surfaces 
 
The following theorem clarifies the relationship between three different Pareto surfaces 
that have been introduced in section 2.1. The proof of this theorem is also given in the 
Appendix.    10 
 
Theorem 2:  
If Gσ is an increasing function for each Cσ ∈ , and is an increasing function of 
| |D x rσ σ−   for each Tσ ∈ , then 
 DVO HEC DD⊂ ⊂X X X  (4) 15 
 
Relation (4) encompasses two important messages. The first message comes from the 
relation DOEC D⊂X X . It implies that a larger Pareto surface is explored by adjusting 
voxel-based weighting factors than by adapting organ-based weighting factors, possibly 
leading to a plan with better trade-offs among different clinical criteria. In fact, we are 20 
exploring different parts of the large Pareto surface DDX by using different set of the 
organ evaluation criteria in the organ-based model. That is, the organ-based problem 
picks certain plans out of the Pareto surface DDX based on the given OEC, and leaves out 
others as the non-Pareto plans. However, the part of the DDX  that is not navigated by this 
approach may contain some more desirable plans, because there is generally no scientific 25 
or fundamental theory behind choosing OEC. 
The second message can be drawn from the relation DOEC VH⊂X X , which states that 
the plans generated by the organ-based model are already DVH Pareto, where a uniform 
weighting factor is assigned to all voxels within an organ. Therefore, it is impossible to 
improve some parts of the DVH curves without worsening others by allocating the non-30 
uniform weights to voxels. In particular, by adjusting the voxel-based weights after the 
organ-based weight adjustment, it is impossible to improve treatment plans in terms of 
DVH criteria at no cost. However, this statement does not exclude the possibility of 
improving the plan at a small cost (Cotrutz and Xing, 2002, 2003; Wu et al., 2003; Yang 
and Xing, 2004; Shou et al., 2005). 35 
 
3. Treatment Plan Optimization by Using Quadratic Penalty Functions 
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In this section, we will elaborate on the results of the above two theorems by 
considering a specific problem with a popular quadratic penalty function. The 
comparison between voxel weighting factor adjustment and voxel reference dose 
adjustment is provided as well. The quadratic dose function has been a very popular 
choice in IMRT treatment plan optimization. Using a quadratic function makes it possible 5 
to get rid of the absolute function in (3), and we can also take advantage of the existing 
efficient algorithms developed for the quadratic optimization problems (Breedveld et al., 
2006). The rest of this section is devoted to the organ-based and voxel-based parameter 
adjustment by employing a quadratic penalty function.  
  10 
3.1 Organ-Dependent Parameter Adjustment  
 
The following problem illustrates a typical organ-based quadratic optimization model for 
IMRT:     
 0
22( )min ( )x j j
C Tj v j v
w x r w xD rD
σ σ
σ σ σ σ
σ σ
≥ +
∈ ∈∈ ∈
+− −∑ ∑∑ ∑  (5) 15 
Where a+ denotes the vector a with all negative elements replaced by zeros. The weights
(for )w Sσ σ ∈  are the parameters that we need to fine-tune to get a plan with desirable 
trade-offs. This can be done by a trial-and-error based approach or by using a heuristic 
update scheme, e.g. developed by Xing et al. (Xing et al., 1999b; Xing et al., 1999a). For 
tumor voxels, reference doses ( ,  r Tσ σ ∈ ) are the prescribed doses given by the 20 
clinicians, but for OARs they are parameters, which are adjusted to reshape the DVH 
curves. In fact, the objective function focuses on the particular tail parts of the DVH 
curves for OARs by considering penalty only for doses which are higher than the 
reference doses.    
For an OAR, the penalty function in Problem (5) is not an increasing function, 25 
because it does not differentiate the doses that are lower than the reference dose. Hence, 
the conditions of Theorem 1 are not satisfied and Pareto optimality might be lost. The 
conditions are satisfied only if the reference doses are equal to zero for all OAR voxels. 
Problem (6) overcomes this issue by penalizing the doses lower than the reference dose 
with a linear penalty function and doses higher than the reference dose with an extra 30 
quadratic dose function. The conditions of Theorem 1 are then fulfilled for this problem, 
and hence, the Pareto optimality is guaranteed. In fact, the main idea for reshaping the 
DVH curves is to focus more on certain parts of the DVH by considering the penalty only 
for over-doses2. Instead of penalizing only for over-doses, Problem (6) reshapes the DVH 
by penalizing over-doses more than the under-doses. 35 
 220min (( ) ) )(x j j j
C T j vj v
w x x r wD x rD D
σ σ
σ σ σ σ
σ σ
≥ +
∈ ∈∈ ∈
++ − −∑ ∑∑ ∑  (6) 
                                                      
2 Doses those are higher than the reference doses. 
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3.2 Voxel-Dependent Weight Adjustment  
 
Cotrutz and Xing (2002) and  (2003), and subsequently Yang and Xing (2004) and  Shou 
et al. (2005), extended their previous work on organ-based quadratic objective function to 5 
the voxel-based quadratic model. Wu et al. (2003) proposed their systematic approach to 
adjust the weighting factors per voxel to modify the initial plan and guide it to clinically 
acceptable one. Breedveld et al. (2007) introduced their voxel-based automatic treatment 
planning in order to generate a plan that complies with all or at least the most important 
given DVH and maximum-dose constraints. They all employed the following voxel-10 
based quadratic model: 
 20
2m ( ) )in (x j j j j
C Tj jv v
w x w xD D r
σ σ
σ σ σ
σ σ
≥
∈ ∈∈ ∈
−+∑ ∑∑ ∑  (7) 
Since the conditions of Theorems 1 and 2 are satisfied in above problem, we can take 
advantage of these theorem’s results. According to Theorem 1, all plans obtained by 
weighting factor adoption are Pareto, and moreover, almost the entire Pareto surface 15 
could be characterized by changing the weighting factors. Regarding Theorem 2, if the 
plan is achieved by adjusting the organ-based weights, we cannot expect to improve some 
parts of the DVH at no cost by employing the voxel-based model; however, we can 
expect to improve some parts at a reasonable cost since we are able to explore some 
previously missed parts of the Pareto surface. These facts will be demonstrated in the 20 
following case study. 
 
3.3 Organ-based Model Versus Voxel-based Model: A Case Study 
 
We studied a gynecologic cancer case that has been planned previously using the Eclipse 25 
treatment planning system (Varian Medical System, Palo Alto, CA). The approved plan 
is replicated by using our in-house GPU-based dose and optimization engines to compare 
the organ-based and voxel-based models on a fair ground. The organ and voxel weighting 
factors are adjusted automatically and iteratively based on the deviation from the 
approved plan (see Li et al. (2012) for details about weight adjustments). The results are 30 
illustrated in Figure 1, where the solid lines represent DVHs for the plan generated by a 
voxel-based model, and the dashed lines are for the plan generated by an organ-based 
model. Comparing these two plans, it is clear that by utilizing non-uniform weights to 
different voxels in an organ, the sigmoid and rectum doses are improved significantly, 
and the PTV over-dosing and bladder dose are improved too at a reasonable cost of doses 35 
to the body, bowel and pelvic bone marrow (PBM). While it is a clinical question as for 
which of the two plans is more preferable, voxel weighting factors offers a big freedom to 
handle the tradeoffs among organs. This occurrence can also be observed in the case 
studies provided in other voxel-dependent research works (Cotrutz and Xing, 2002, 2003; 
Wu et al., 2003; Yang and Xing, 2004; Shou et al., 2005)        40 
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Figure 1: Comparison of the treatment plans optimized with a voxel-based model and an organ-
based model for a GYN case. Solid line: voxel-based model; Dashed line: organ-based model. The 
vertical blue line indicates the prescription PTV dose.  5 
   
3.4 Voxel-Dependent Reference Dose Adjustment 
 
In addition to changing voxel weighting factors, voxel reference doses can also be 
adjusted as optimization parameters to produce a desirable plan as in the following 10 
model:  
 20 ( )minx j j
S j v
Dw x r
σ
σ
σ
≥
∈ ∈
−∑ ∑  (8)               
As opposed to the weighting factor adjustment, the Pareto optimality is not guaranteed by 
adjusting reference doses. In fact, the penalty functions for the OAR and PTV voxels in 
the above problem are not necessarily the increasing functions of jD x  and | |jD x r
σ−  15 
which makes the conditions of Theorem 1 unsatisfied.  
Apart from the Pareto optimality, Problems (7) and (8) differ in the way that they are 
adjusting voxel penalty terms in the objective function in order to catch the desirable 
trade-offs. By fine-tuning voxel-based weighting factors, we are adjusting the quadratic 
penalty term of each voxel in the objective function, while the linear penalty term of each 20 
voxel is adopted by updating the reference doses. To clarify this, let us extend the penalty 
term for a specific voxel j in Problem (8) as follows: 
2 2(( ) 2 ( ) )j j j jD x r D xw r
σ − +  
 
PTV 
Sigmoid 
 
Bladder Rectum 
Body 
 
PBM 
Bowel 
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Since 2jw r
σ is independent of the decision variable x , it does not affect the optimal 
solution. Thus, for each voxel there are a quadratic and a linear penalty term in the 
objective function and only is the linear part altered by updating the reference doses. In 
contrast, for the cases where weighting factors are adjusted, the quadratic terms are 
affected. What we can conclude from the aforementioned fact is that the smaller change 5 
is expected in the current plan by altering reference doses than weighting factors.  
 
4. Discussion and Conclusions 
 
In this paper, we presented two theorems behind the organ- and the voxel-based 10 
optimization models by introducing a new mathematical framework for treatment plan 
optimization. The new framework clarifies the main pros and cons of the different 
parameter adjustment strategies, and makes it possible to answer some interesting and 
important questions arisen in these contexts.  
The results of the new framework could be summarized as follows: 15 
1- While selecting an appropriate objective function has an impact on the quality of 
the optimized plan using an organ-based model due to the fact the different 
objective functions may correspond to different parts of the Pareto surface, the 
entire Pareto surface could be characterized by a voxel-based model as long as 
the voxel penalty functions and their derivatives are appropriate increasing 20 
functions.     
2- Comparing the organ-based and the voxel-based model, the former only captures 
some parts of the Pareto surface depending on the given organ evaluation criteria. 
Therefore, we are more likely to get a plan with more desirable trade-offs by 
exploring the entire Pareto surface via the voxel-based model. 25 
3- By allocating the non-uniform importance factors, rather than the uniform 
weights, we cannot expect to improve some parts of the DVH at no cost; 
however, possibly we would be able to improve some parts of the DVH at a 
small cost by exploring the missing parts of the Pareto surface. 
4- In contrary to the voxel weight adjustment, the Pareto optimality is not 30 
guaranteed by tuning voxel reference doses. Moreover, since changing the 
reference doses is equivalent to updating the linear penalty term of each voxel, it 
is expected that smaller changes will occur in the plan comparing with changing 
the weighting factors. 
5-  In organ-based model, when we are changing the reference doses in order to 35 
reshape the DVH curves, it is better to consider the linear penalty term rather 
than the zero penalty for doses lower than the reference dose to assure the Pareto 
optimality.   
Yet, one practical difficulty in the voxel-based optimization models is the 
dramatically increased number of parameters. We developed a heuristic method to 40 
iteratively adjust the voxel weighting factors based on the deviation to the desired DVH.  
A research topic that needs to be pursued in future is developing an efficient and 
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systematic approach to adjust the weighting factors in order to efficiently navigate 
through the Pareto surface to choose a clinically acceptable plan.  
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Appendix 
 
Throughout the proofs we need some fundamental results from multi-criteria 
optimization which can be found in both (Ehrgott, 2005) and (Miettinen, 1999).  
 5 
A.1. Proof of Theorem 1: 
a) For an arbitrary positive weight vector, an optimal solution of Problem (2) is Pareto 
with respect to the objective function . It implies that there is no possibility to decrease 
some without increasing others, which means that the optimal solution is Pareto in 
terms of the evaluation criteria. Moreover, each properly Pareto point can be generated 10 
with some positive weights. 
 
b) Let  be an optimal solution of Problem (1) for an arbitrary positive weight vector. 
Then,  is a Pareto solution of . Since function is increasing for each 
and increasing of  for each  then is a Pareto 15 
solution of Problem (A1) as well. Now, by the definition of dose distribution Pareto 
optimality, it is obvious that each Pareto solution of Problem (A1) is Pareto in terms of 
the dose distribution, i.e., .  
  (A1)      
 20 
c) Let be an arbitrary Pareto solution in terms of the dose distribution. We need 
to prove that is an optimal solution of Problem (1) for some positive weights. 
According to the definition of dose distribution Pareto optimality, is a Pareto solution 
of Problem (A1) which can be converted to the following equivalent linear multi-criteria 
optimization problem by change of variables (Murty, 1983):  25 
  (A2)   
If we define , then it can be readily 
shown that is a Pareto solution of Problem (A2). Due to the linearity of 
(A2), there is a positive weight vector for which solves the 
corresponding weighted version of the above problem. Now, it is not difficult to show 30 
that solves the weighted version of Problem (A1) corresponding to  It implies that  
is a so-called properly Pareto solution of this problem. Since and its derivative are 
increasing functions with respect to the objective functions of Problem (A1) and the 
derivative of  is positive on its domain, is a properly Pareto solution of 
G
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 as well (Zarepisheh, 2011). So, there are some positive weights for which
is an optimal solution of Problem (1) due to the strict convexity of .  
 
A.2. Proof of Theorem 2: 
 First of all, we need to provide a mathematical definition for improvement in DVH 5 
curves. Let denote the permutation that sorts every given vector in an ascending 
order. Then, for a specific structure improvement in DVH curve is 
equivalent to the componentwise decrease in vector . Now, we 
prove the relations and separately.   
( ): If we prove that for each structure , the corresponding objective 10 
function decreases as the DVH curve of that structure improves, and does not 
change as the DVH curve remains unchanged, then the relation can be 
proved easily by contradiction. We prove this property for two different cases and 
individually.  
( ): Let be two feasible solutions of (2). At first, consider the case for which 15 
these two plans produce the same DVH curves for structure  For this case we need to 
show that  The relation , and subsequently
, can be deduced from the fact that these two plans generate 
the same DVH curves for structure  Since the objective function is symmetric and 
indifferent to the permutation, we have20 
, and hence,  Now, consider the case 
for which plan generates the better DVH curve than plan for structure  In this case, 
we need to prove that  Since generates the better DVH curve 
than  we have 3 . Moreover, the objective function is an 
increasing function concluding that . Now, the relation 25 
can be obtained by taking into account the symmetric property of 
       
( ): The main idea to prove this part is same as the previous part. If and generate 
the same DVH curves for structure  then and so
 Since the objective function is symmetric 30 
with respect to the , we have  Now, if the 
DVH curve of plan for structure is better than of plan  then 
                                                      
3  
0min ( )x F Dx≥
x F
(.)π
/C Tσ σ∈ ∈
( ) / (| |)D x D x rσ σ σπ π −
DOEC VH⊂X X DDVH D⊂X X
DOEC VH⊂X X σ
Gσ Gσ
DOEC VH⊂X X
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. The relation can 
be achieved by taking into account the increasing and symmetric properties of with 
respect to . 
( ): We argue by contradiction to prove this part. Suppose that does not 
belong to , then we need to prove that does not either belong to .  5 
means that there exists another plan like with better amount of radiation in some voxels. 
Therefore, for each we have and 
relation  holds at least for one structure. Relations and  
result in and   
respectively. It shows that some DVH curves of plan  could be improved without 10 
deteriorating the others, meaning , which completes the proof.  
  
| |) | |( )ˆ(xD Dr x rσ σ σ σπ π− −ò ˆ| |( |)() |G x r G xD D rσ σ σ σ σ σ<− −
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